Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.

Shane E, Shiau S, Recker RR, Lappe JM, Agarwal S, Kamanda-Kosseh M, Bucovsky M, Stubby J, Cohen A

The Journal of clinical endocrinology and metabolism1 Mar 2022Cited by 37 (Europe PMC)

PMID34849989PMCIDPMC9122662DOI10.1210/clinem/dgab850PepBankPUB-34849989

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, total hip BMD increased during denosumab after teriparatide.
In plain wordsIn premenopausal women with idiopathic osteoporosis, total hip bone density increased during denosumab after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD during denosumab after teriparatide
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD change
2.9%
12 months denosumab
BMD change
4.6%
24 months denosumab
Source sentences
Summary
After completing teriparatide, 32 participants took denosumab for 12 months and 29 for 24 months, with statistically significant increases in BMD at the LS (5.2 ± 2.6% and 6.9 ± 2.6%), TH (2.9 ± 2.4% and 4.6 ± 2.8%), and FN (3.0 ± 3.8% and 4.7 ± 4.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes include change in 12-month BMD at other sites, 24-month BMD at all sites, trabecular bone score (TBS), and bone turnover markers (BTMs).
Summary · context
This was a preplanned phase 2B extension study.
Summary · context
Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3484998902
02HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, femoral neck BMD increased during denosumab after teriparatide.
In plain wordsIn premenopausal women with idiopathic osteoporosis, femoral neck bone density increased during denosumab after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD during denosumab after teriparatide
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD change
3%
12 months denosumab
BMD change
4.7%
24 months denosumab
Source sentences
Summary
After completing teriparatide, 32 participants took denosumab for 12 months and 29 for 24 months, with statistically significant increases in BMD at the LS (5.2 ± 2.6% and 6.9 ± 2.6%), TH (2.9 ± 2.4% and 4.6 ± 2.8%), and FN (3.0 ± 3.8% and 4.7 ± 4.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes include change in 12-month BMD at other sites, 24-month BMD at all sites, trabecular bone score (TBS), and bone turnover markers (BTMs).
Summary · context
This was a preplanned phase 2B extension study.
Summary · context
Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3484998903
03HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis receiving denosumab after teriparatide, trabecular bone score increased.
In plain wordsIn premenopausal women with idiopathic osteoporosis receiving denosumab after teriparatide, trabecular bone score increased.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular bone score
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
TBS change
5.8%
Denosumab after teriparatide
Source sentences
Summary
TBS increased by 5.8 ± 5.6% (P < .001).
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes include change in 12-month BMD at other sites, 24-month BMD at all sites, trabecular bone score (TBS), and bone turnover markers (BTMs).
Summary · context
This was a preplanned phase 2B extension study.
Summary · context
Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3484998907
04HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women receiving denosumab after teriparatide, serum bone turnover markers fell by three months and remained suppressed through twelve months.
In plain wordsIn premenopausal women receiving denosumab after teriparatide, blood bone-turnover markers fell and remained suppressed.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum bone turnover markers
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
BTM reduction
75 to 85%
By 3 months denosumab
Source sentences
Summary
Serum BTM decreased by 75% to 85% by 3 months and remained suppressed through 12 months of denosumab.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes include change in 12-month BMD at other sites, 24-month BMD at all sites, trabecular bone score (TBS), and bone turnover markers (BTMs).
Summary · context
This was a preplanned phase 2B extension study.
Summary · context
Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3484998908
05HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, lumbar spine BMD increased during denosumab after teriparatide.
In plain wordsIn premenopausal women with idiopathic osteoporosis, spine bone density increased during denosumab after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD during denosumab after teriparatide
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD change
5.2%
12 months denosumab
BMD change
6.9%
24 months denosumab
Source sentences
Summary
After completing teriparatide, 32 participants took denosumab for 12 months and 29 for 24 months, with statistically significant increases in BMD at the LS (5.2 ± 2.6% and 6.9 ± 2.6%), TH (2.9 ± 2.4% and 4.6 ± 2.8%), and FN (3.0 ± 3.8% and 4.7 ± 4.9%).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a preplanned phase 2B extension study.
Summary · context
Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3484998901
06HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, lumbar spine BMD increased over sequential teriparatide and denosumab treatment.
In plain wordsIn premenopausal women with idiopathic osteoporosis, spine bone density increased over sequential teriparatide and denosumab treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSequential treatment lumbar spine BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD change
21.9%
Entire sequential treatment period
Source sentences
Summary
Over the entire 24-month teriparatide and 24-month denosumab treatment period, BMD increased by 21.9 ± 7.8% at the LS, 9.8 ± 4.6% at the TH, and 9.5 ± 4.7% at the FN (all P < .0001).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a preplanned phase 2B extension study.
Summary · context
Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3484998904
07HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, total hip BMD increased over sequential teriparatide and denosumab treatment.
In plain wordsIn premenopausal women with idiopathic osteoporosis, total hip bone density increased over sequential teriparatide and denosumab treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSequential treatment total hip BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD change
9.8%
Entire sequential treatment period
Source sentences
Summary
Over the entire 24-month teriparatide and 24-month denosumab treatment period, BMD increased by 21.9 ± 7.8% at the LS, 9.8 ± 4.6% at the TH, and 9.5 ± 4.7% at the FN (all P < .0001).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a preplanned phase 2B extension study.
Summary · context
Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3484998905
08HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, femoral neck BMD increased over sequential teriparatide and denosumab treatment.
In plain wordsIn premenopausal women with idiopathic osteoporosis, femoral neck bone density increased over sequential teriparatide and denosumab treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSequential treatment femoral neck BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD change
9.5%
Entire sequential treatment period
Source sentences
Summary
Over the entire 24-month teriparatide and 24-month denosumab treatment period, BMD increased by 21.9 ± 7.8% at the LS, 9.8 ± 4.6% at the TH, and 9.5 ± 4.7% at the FN (all P < .0001).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a preplanned phase 2B extension study.
Summary · context
Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3484998906
09HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialSafety outcome
In premenopausal women with idiopathic osteoporosis, denosumab after teriparatide was generally well tolerated.
In plain wordsIn premenopausal women with idiopathic osteoporosis, denosumab after teriparatide was generally well tolerated.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableDenosumab tolerability after teriparatide
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
Denosumab was generally well tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a preplanned phase 2B extension study.
Summary · context
Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3484998909

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT02049866

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

Elizabeth Shanen = 3319 Nov 2014 to 23 Dec 2021

Adult Idiopathic Generalized Osteoporosis

Trial page ClinicalTrials.govUpdated 12 Dec 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.